Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Hiroyuki AraiTakashi TsudaYu SunakawaMototsugu ShimokawaKohei AkiyoshiShinya TokunagaHirokazu ShojiKenji KuniedaMasahito KotakaToshihiko MatsumotoYusuke NagataTakuro MizukamiFumitaka MizukiKathleen D DanenbergNarikazu BokuTakako Eguchi NakajimaPublished in: Cancer medicine (2024)
Our novel treatment strategy delivered acceptable survival outcomes and reduced severe dermatologic toxicities.